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Abstract:  Objectives: (1) to describe the frequency of sleep apnea in patients with acromegaly; (2) to identify the 
proportion of candidates for treatment with positive airway pressure; and, (3) to report our experience with the positive 
pressure titration process in acromegaly patients. 
Methods: A cross-sectional study that included the acromegaly cohort at the Centro Medico Nacional “20 de Noviembre” 
in Mexico City (n=44). A standard polysomnography (PSG) was carried out for each patient. A second PSG was done for 
purposes of CPAP titration. 
Results: A total of 35 patients were studied (80% of the cohort, 20 [57%] women). Polysomnography results showed that 
34 subjects (97%, 95%CI 91-100%) had apnea hypopnea indexes (AHI)  5. No patient had central apnea. We identified 
19 subjects with AHI 5 and Epworth 10, for a frequency of obstructive sleep apnea syndrome of 54% (95%CI 36-71%). 
A total of 31 patients (88%; 95%CI 77-99%) were deemed to be candidates for positive pressure treatment, but only 8 of 
them accepted CPAP. They required pressures that ranged from 10 to 18 cmH2O. 
Conclusions: Our results confirm a high prevalence of sleep apnea in patients with acromegaly, and provide evidence that 
the majority of those patients are candidates for treatment with positive pressure. Contrary to what has been reported, we 
identified no patients with central apnea. 
Keywords: Acromegaly, sleep, sleep apnea, sleep-disordered breathing, growth hormone. 
INTRODUCTION 
  Acromegaly is a disease characterized by an excessive 
secretion of growth hormone (GH) and insulin-like growth 
factor type 1 (IGF-1) [1]. Though the incidence of this 
illness is low (3-4 cases per million inhabitants per year) and 
there is a wide range of treatment modalities available, life 
expectancy is reduced by at least 10 years due, primarily, to 
mortality caused by cardiovascular factors [2]. 
  Though information exists on the high frequency of SDB 
in patients with acromegaly, those disorders have been 
poorly characterized and little is known about the daytime 
symptoms of patients with acromegaly who experience SDB. 
Finally, there is no data on positive pressure titration as a 
therapeutic measure applied in acromegaly patients [3-6]. 
  Therefore, the objectives of this study were, first, to 
describe the frequency of sleep apnea in a cohort of patients 
with acromegaly; second, to identify the proportion of   
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patients with acromegaly and sleep apnea that are candidates 
for treatment with positive pressure; and, third, to report our 
experience with the titration process of positive pressure in 
patients with this disease. 
METHODS 
  This study was approved by the Science and Bioethics 
Committee of the Instituto Nacional de Enfermedades 
Respiratorias (code C04-09). Participants in the study signed 
an informed consent form. Data confidentiality was 
maintained at all times. 
  This is a cross-sectional study in which all patients of the 
acromegaly cohort at the Centro Medico Nacional “ 20 de 
Noviembre” in Mexico City were invited to participate. At 
the time the study was undertaken that cohort included 44 
patients. The diagnosis of acromegaly was made according 
to the accepted international criteria [7-9]. 
  Once patients had agreed to participate in the study, they 
filled in questionnaires on their habits and symptoms related 
to sleep, including a validated Spanish version of the 
Epworth Sleepiness Scale (ESS) [10]. Anthropometric 
measurements were made using an electronic scale 
(Tanita™, Japan, precision ±200g), and a stadimeter (SECA Sleep Apnea and Acromegaly  The Open Respiratory Medicine Journal, 2012, Volume 6    29 
240™, Hamburg, Germany, precision ±0.2cm). Body mass 
index (BMI) was obtained through the following formula: 
BMI = (weight/high
2). Neck circumference was measured at 
the level of the cricoid cartilage using a non-extendible, 
polycarbonate tape measure. Blood pressure was measured 
using a mercury manometer after patients had remained at 
rest for 5 minutes. All measurements were made by a single 
researcher (DHG). 
  The polysomnography studies were conducted using a 
16-channel Grass Instrument (model 15LT-PSGA, Gamma 
4.1 version, West Warwick, Rhode Island, USA), or a 32-
channel Alice Sleepware device (version 5, model 1018958, 
Respironics brand, Murrysville, Pennsylvania, USA). All 
studies were conducted in accordance with the American 
Academy of Sleep Medicine’s recommendations (AASM, 
2007) [11]. The montage utilized included 
electroencephalography derivations: frontal, central and right 
occipital (F4-M1, C4-M1, O2-M1), left and right 
electrooculograms (EOG), electromyograms (EMG) of the 
chin, EMGs of the tibialis anterior muscle to detect leg 
movements, and electrocardiogram channel obtained through 
a unipolar derivation. Airflow was measured simultaneously 
using an oronasal thermistor and a pressure transducer 
(Respironics Sleep Sense™ brand, Murrysville, 
Pennsylvania, USA), while respiratory movements of the 
thorax and abdomen were determined through inductance 
plethysmography (Respiband™; New York, USA, or bands, 
Pro tech™, Murrysville, Pennsylvania, USA). The state of 
oxygenation was measured by pulse oximetry (Massimo™ 
set Irvine, USA). The studies were assessed in 30-second 
epochs in order to identify sleep stages in accordance with 
the guidelines established by the AASM (2007) [11]. Apnea 
was considered to be obstructive when a decline in the 
thermal sensor’s peak 90% from baseline for at least 10 
seconds was observed, together with the presence of 
continuous or augmented respiratory movement throughout 
the event. Central apnea, meanwhile, was defined as a 
decline in the peak of the thermal sensor 90% from baseline 
for at least 10 seconds with an absence of respiratory 
movement during the entire event. Mixed apnea was 
diagnosed by a decline in the peak of the thermal sensor 
90% from baseline for at least 10 seconds associated with 
an absence of inspiratory effort at the initial part of the event, 
followed by the resumption of that effort during the second 
part of the event. Hypopnea was identified on the basis of a 
reduction 30% in the signal from the pressure cannula with 
respect to baseline for a duration of at least 10 seconds, 
associated with desaturation 4% and when at least 90% of 
the time of the event satisfied the reduction criteria for the 
pressure signal. 
  Patients with severe apnea (apnea hypopnea index, AHI 
>30), as well as those with AHI between 5 and 30 with 
Epworth 10 points, and patients with AHI between 5 and 30 
with Epworth below 10 points and high cardiovascular risk 
were judged to be candidates for CPAP treatment [12]. 
Statistical Analysis 
  Most of the variables showed asymmetrical distributions; 
therefore, data are presented as medians, interquartile 
intervals (IQI) and minimum and maximum values. The 
categorical variables were described as frequencies and 
percentages using 95% confidence intervals (95%CI). 
Associations were explored using Spearman’s coefficient 
correlation, while group comparisons were carried out –as 
appropriate– using the Wilcoxon Rank-Sum Test or the X
2. 
Data analysis was conducted using a commercially available 
statistical package (Stata, release 9.2, StataCorp, College 
Station, TX, USA). 
RESULTS 
  The original cohort consisted of 44 patients, but 9 
declined to participate. Thus, 35 patients were studied 
(response rate 80%). No differences were found in age, 
gender, ESS or IGF-1 between responders (n=35) vs non-
responders (n=9).  Of these individuals, 20 were women 
(57%) and 15 were men (43%). Table 1 shows their general 
characteristics. 
Table 1.  General Characteristics of the Patients 
 
Parameter  Value 
Age (years)*  51 (39 – 63) 13 – 85 
Age at diagnosis (years)*  47 (35 – 52) (13 – 71) 
Weight (Kg)  75 (68 – 88) 49 – 137 
Height (m)*  1.62 (1.56 – 1.70) 1.43 – 1.82 
BMI (Kgm
-2)*  29 (26 – 33) 22 – 46 
NC (cm)*  38 (35 – 40) 32 – 50 
Years since diagnosis of acromegaly*  4 (3 – 10) 0 – 30 
Patients subjected to surgery
a n (%)   28 (80) 
Patients subjected to radiation therapy n (%)  14 (40) 
Months receiving octreotide*  30 (20 – 36) 3 – 62 
Controlled patients n (%)   28 (80) 
Uncontrolled patients n (%)  7 (20) 
Sleep-Related Symptoms 
Patients with snoring n (%)  31 (91) 
Patients with insomnia n (%)  26 (76) 
Patients with observed apneas n (%)  10 (30) 
Hypertension
b n (%)  20 (59) 
Mallampati score*  2 (2 – 3) 1 - 4 
Tonsillar grade
c *  1 (1 – 2) 0 - 3 
Daytime SpO2%*  93 (92 – 95) 86 - 96 
Epworth Scale score*  10 (6 – 15) 2 – 24 
Epworth 10 n (%)  20 (59) 
BMI: body mass index, NC: neck circumference, SpO2%: oxygen saturation by pulse 
oxymetry. 
*Mean (interquartile Interval) min. – max. 
aSurgery to resect the pituitary adenoma. 
bMedical diagnosis of hypertension; or on antihypertensive treatment; or blood pressure 
greater than 140/90 mmHg. 
cGrade 0: tonsillectomy; grade 1: tonsils were in the tonsillar fossa; grade 2: tonsils 
were visible behind the anterior pillars; grade 3: tonsils extended three-quarters of the 
way to the midline; grade 4: tonsils were completely obstructing the airway [25]. 
 
 Table  2 shows the results of the polysomnography 
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interpretation, sleep efficiency had to reach at least the level 
of 80%. One patient was studied on two occasions because 
on the first sleep efficiency was below 80%. Sleep efficiency 
for the group as a whole showed a mean of 87% (IQI 82-92). 
In the majority of patients (97%; 95%CI 91-100), tests 
revealed an AHI considered “abnormal” (5 events/hour), 
and in 60% of patients, AHI was above the cutoff point for 
“severity” (30 events/hour). Nineteen patients (54%, 
95%CI 36-71%) satisfied the usual criteria of obstructive 
sleep apnea syndrome (AHI 5 events/hour with and 
Epworth score 10). Alterations of sleep architecture were 
documented: the mean for slow-wave sleep was 16% (IQI 
10-21), while that of REM sleep (R sleep) was 15% (IQI 13-
18), with an average of 30 alerts per hour of sleep. Upon 
comparing men and women, no significant differences were 
found in the frequency of apnea, the severity of the disease, 
the need for treatment, the Epworth Sleepiness Scale, or any 
of the other variables evaluated (Table 3). 
Table 2.  Results of Polysomnography Studies 
 
Parameter  Value 
Sleep efficiency (%)*  87 (82 – 92) 56 - 98 
Latency to 1
st stage of sleep (minutes)*  16 (12-21) 0 - 59 
Latency to REM (minutes)*  89 (74 – 128) 50 - 339 
 N1 (%)*  14 (12 – 19) 3.2 - 52 
 N2 (%)*  51 (46 – 58) 37 - 71 
 N3 (%)*  16 (10 – 21) 0.6 - 31 
NREM (%)*  85 (82 – 88) 72 - 92 
REM (%)*  15 (13 -18) 9 - 27 
Index of arousals*   30 (23 – 42) 8 - 82 
Index of respiratory arousals*  16 (5 – 26) 0 - 66 
Central apneas*  1 (0 – 5) 0 - 97 
Mixed apneas*  0.2 (0 – 2.4) 0 - 60 
Obstructive apneas*  54 (9 – 146) 1 - 637 
Hypopneas*  169 (82 – 219) 0 - 327 
Central apnea index (events/hr)*  0.1 (0- 0.7) 0.1 – 14.2 
Obstructive apnea index (events/hr)*  9 (1.3 – 20) 0.1 – 84 
AHI (events/hr)*  34 (22 – 57) 3.3 – 108 
AHI <5 n (%)  1 (3) 
AHI 5 and <15, n (%)  7 (20) 
AHI 15 and <30, n (%)  6 (17) 
AHI 30, n (%)  21 (60) 
SpO2 while laying awake*  93 (90 – 94) 82 – 96 
Average SpO2 during sleep*  90 (87 – 92) 62 – 95 
REM SpO2*  89 (86 – 92) 56 – 95 
NREM SpO2*  90 (87 – 92) 67 – 95 
AHI  5 and Epworth  10, n (%)  19 (54) 
REM: rapid eye-movement sleep, NREM: non-rapid eye-movement sleep, AHI: apnea-
hypopnea index, SpO2: percentage of saturation by pulse oxymetry. 
*Mean (interquartile interval) min. – max. 
 
  Seven patients had “uncontrolled” acromegaly, though 
IGF-1 levels were not found to be associated with either the 
AHI or central apneas. The correlation between the IGF-1 
levels and the index of central apneas was not significant (p 
= 0.98), nor did we find any difference between the 
controlled (n=28) versus the uncontrolled patients (n=7) with 
respect to sleep architecture or respiratory indexes. 
  All patients received octreotide for at least 3 months from 
the onset of treatment. The study did not demonstrate any 
associations between the duration of treatment and the 
severity of the apnea (rs= 0.13), or between the degree of 
sleepiness and the activity of the acromegaly (rs = 0.15) or 
the number of years since diagnosis (rs = -0.11), or between 
AHI and the Epworth Scale (rs = 0.03). A weak association 
between AHI and body mass index was found (rs= 0.35, p= 
0.03), but no association with neck circumference (rs= 0.16, 
p=0.37) was documented. We also compared patients 
according to excessive daytime sleepiness (ESS 10 vs ESS 
<10) but found no significant differences in age, BMI, IGF-
1, months of treatment with octreotide, or years since 
diagnosis. 
  Of the 35 patients studied, 31 were considered candidates 
for CPAP treatment (88%, 95%CI 77-99%). Those patients 
were classified as follows: (a) 9 (26%) with AHI 30 
events/hour; (b) 19 (54%) with AHI between 5 and 30 
events/hour and Epworth 10; and, (c) 3 (8%) with AHI 
between 5 and 30 events/hour with Epworth <10 and 
systemic arterial hypertension. 
  The 31 patients judged to be candidates for treatment 
with positive pressure were invited to undergo a second 
polysomnograph for pressure titration, but only 8 of them 
(26%) agreed to undergo the test. These results are shown in 
Table 4. Three of these patients were titrated using both the 
CPAP and bi-level methods (patients 1, 2 and 6), but the 
latter showed no advantages over CPAP in terms of sleep 
architecture, residual AHI, tolerance, or gas exchange. One 
patient did not tolerate CPAP. Optimal CPAP pressures 
ranged from 12 to 18 cmH2O. 
DISCUSSION 
  The principal results of this study are as follows: (1) 
almost all patients (97%) presented abnormal AHI; (2) just 
over half of the patients (54%) had AHI 5 and Epworth 
10; (3) 88% of patients were candidates for CPAP 
treatment; (4) contrary to reports by other authors, we did 
not identify patients with central apnea in our cohort; and, 
(5) CPAP treatment seems to be efficient in most patients 
with acromegaly; while the bi-level method does not appear 
to have advantages over CPAP. 
  The prevalence reported for sleep apnea in patients with 
acromegaly varies from 19 to 81%, depending on the 
methods and diagnosis criteria used [13]. Given that these 
figures differ from the prevalence of sleep apnea in the 
general population –2% and 4% for women and men, 
respectively–[14,15] it is suggested that acromegaly is a risk 
factor for the development of sleep apnea. In this study, the 
diagnostic method utilized was nocturnal polysomnography, 
which allowed researchers to identify (according to current 
staging standards), that 97% of patients with acromegaly 
have abnormal AHI, and that the prevalence of obstructive 
sleep apnea syndrome –defined as AHI 5 events/hour and Sleep Apnea and Acromegaly  The Open Respiratory Medicine Journal, 2012, Volume 6    31 
Epworth 10– was 54%. To the best of our knowledge, this 
is the first report on the frequency of sleep apnea in patients 
with acromegaly to utilize the current scoring rules and 
recommendations, published by the American Academy of 
Sleep Medicine in 2007 [11]. 
  Though we cannot affirm that an AHI 5 in patients with 
acromegaly is equally deleterious as in patients who do not 
suffer from this disease, intuitively we could consider that 
the high cardiovascular risk seen in patients with acromegaly 
might be due, at least in part, to their high frequency of sleep 
Table 3.  Comparison of Polysomnographic Findings Between Men and Women 
 
Parameter  Women (n= 20)  Men (n= 15)  p Value 
AHI <5 n(%)  0  1 (7)  0.24 
AHI 5 n(%)  20 (100)  14 (93)  0.25 
AHI 5 y <15, n(%)  3 (15)  4 (27)  0.39 
AHI 15 y <30, n(%)  4 (20)  2 (13)  0.60 
AHI 30, n(%)  13 (65)  8 (53)  0.48 
Habitual snorer, n(%)  20 (100)  12 (80)  0.03 
Candidate for CPAP, n(%)  19 (95)  12 (80)  0.16 
Epworth score*  10 (6 – 18) 2 - 22  10 (7 – 12) 2 - 24  0.54 
Sleep Efficiency (%)*  86 (79 – 91) 62 - 95  88 (84 – 92) 57 - 98  0.30 
Latency to 1
st stage (min)*  18 (11 – 25) 4 - 59  16 (12 – 19) 0 - 25  0.31 
Latency to REM (min)*  89 (84 – 128) 52 - 339  76 (67 – 128) 50 - 249  0.30 
Stage 1 (%)*  15 (12 – 17) 5 - 28  13 (11 – 25) 3 - 52  0.94 
Stage 2 (%)*  54 (46 – 59) 37 - 71  48 (47 – 56) 39 - 58  0.32 
Stage 3 (%)*  16 (10 – 19) 8 - 31  16 (13 – 23) 1 - 26  0.66 
REM (%)*  15 (13 – 19) 9 - 22  15 (13 – 18) 9 - 27  0.84 
Index of arousals*  30 (24 – 38) 8 - 82  30 (16 – 59) 8 - 70  0.86 
Index of respiratory arousals *  16 (5 – 22) 0 - 63  11 (5 – 53) 0 - 67  0.52 
AHI (events/hour)*  33.4 (29 – 54.5) 11 - 108  39.4 (12 – 76) 3.3 – 87.5  0.96 
Daytime SpO2*  94 (92 – 95) 86 - 96  93 (92 – 95) 88 - 96  0.53 
SpO2 while laying awake*  92 (89 – 94) 82 - 95  93 (90 – 94) 90 - 96  0.37 
Average SpO2 during sleep*  90 (86 – 92) 62 - 95  90 (87 – 93) 70 - 95  0.89 
REM SpO2*  89 (86 – 91) 56 - 95  89 (84 – 93) 63 - 95  0.83 
NREM SpO2*  90 (86 – 92) 69 - 95  90 (88 – 93) 75 - 94  0.97 
AHI: apnea-hypopnea index, CPAP: continuous positive airway pressure, REM: rapid eye-movement sleep, NREM: non-rapid eye-movement sleep, SpO2: percentage of saturation 
by pulse oxymetry. 
*Mean (Interquartile interval) min. – max. 
 
Table 4.  Patients Titrated with CPAP 
 
Patient Gender Age BMI  Epworth  
Scale Score 
Average SpO2  
During Sleep  AHI  CPAP Pressure  
(cmH20) 
Residual AHI  
with CPAP 
Average SpO2  
with CPAP 
 Supplementary  
Oxygen  
1 F  53  30 6  69 108  16  0  84  Yes   
2 M  38  46 15  70  70  18    94  No 
3  M  64  27  12  87  70  Did not tolerate  -  87  Yes 
4 F  34  25  15  91  28  14  3  91  No 
5 F  37  23  20  91  40  10    95  No 
6 M  68  27 11  90  27  12  9  92  No 
7 F  43  30  16  92  51  11    93  No 
8 F  50  42  10  86  54  12  0  91  No 
F: Female. M: Male. BMI: body mass index in Kgm
-2. SpO2: percentage of saturation by pulse oxymetry. AHI: total apnea hypopnea index. 32    The Open Respiratory Medicine Journal, 2012, Volume 6  Hernández-Gordillo et al. 
apnea. Sleep apnea is considered an independent risk factor 
of cardiovascular morbidity;
  nonetheless, the mechanisms 
underlying this association are not well known [16-19]. 
There is evidence to suggest that the hypoxemia-
reoxygenation phenomenon induces an “oxidative” state that 
has harmful consequences for endothelial functioning and 
the atherogenic process, in addition to inducing a systemic 
inflammatory condition. Other mechanisms that cause 
cardiovascular damage include high sympathetic activation, 
changes in intrathoracic pressure and the hypo-hypercapnia 
phenomenon [19]. The participation of these mechanisms in 
the development of cardiovascular diseases in patients with 
acromegaly remains to be clarified. 
  Another significant finding documented by this study is 
that 54% of patients suffer from obstructive sleep apnea 
syndrome (AHI 5 and Epworth 10). Clearly, all those 
patients are candidates for treatment. Upon adding other 
groups who meet the criteria for receiving treatment, it was 
possible to determine that 88% are candidates for CPAP, but 
additional studies are needed to evaluate the effect of CPAP 
on cardiovascular morbidity and mortality in patients with 
acromegaly. Another additional salient point to explore is 
whether the craniofacial abnormalities of such patients 
negatively affect long-term adherence to CPAP. 
  Other factors not associated with the craniofacial 
abnormalities may potentially explain the high frequency of 
sleep apnea observed in patients with acromegaly. For 
example, chronic exposure to high altitudes in untreated 
patients with obstructive sleep apnea aggravates hypoxemia 
and increases sleep-related breathing disturbances due to 
frequent central apneas/hypopneas [20]. This factor could 
lead to an overestimate of the prevalence of sleep apnea in 
our cohort, given that Mexico City is at 2240 meters above 
sea level. However, as shown in Table 2, the AHI observed 
in our patients were due mainly to obstructive, not central, 
disturbances; moreover, they were acclimatized residents of 
Mexico City and previous data from our group (n=23) 
demonstrated that, in healthy people living at that altitude, 
the median of AHI was 3.3 events/hr and sleep architecture 
was similar to that described in other studies carried out at 
sea level [21]. Therefore, we do not believe that altitude is a 
significant element in the high frequency of sleep apnea 
observed in patients with acromegaly. Another potential 
confounder is obesity; however, only a weak association 
between AHI and body mass index was found, and no 
association with neck circumference was recognized; 
suggesting that the high frequency of sleep apnea observed 
in our patients could be predominantly a consequence of 
their craniofacial abnormalities, and not of obesity as is seen 
in the general population [22]. 
  Previous studies have established an association between 
the number of central apneas and the activity of this disease 
(IGF-1 levels). However, we did not encounter this 
association in our patients, and in no case was the presence 
of central apneas above 50% of total AHI. Treatment with 
octreotide may explain this finding, as all patients had been 
taking that medication for at least 3 months, and earlier 
research has shown that this therapy reduces the severity of 
the illness, at the cost of diminishing the number of central 
apneas [23]. 
  Finally, our study has limitations. First, all our patients 
were being treated with octreotide, which impedes us from 
speculating on the frequency of sleep apnea in patients who 
are virgins in terms of treatment. Second, we were unable to 
include control subjects matched for age and BMI, a fact that 
impedes any affirmation as to whether those potential 
confounders may be contributing to the high frequency of 
sleep apnea in patients with acromegaly. Third, the response 
rate to CPAP titration was low (25%), a fact that limits the 
external validity of the data obtained from the titration 
process using positive pressure; however, though we were 
unable to determine why so few patients accepted CPAP, we 
believe that factors other than medical reasons are involved; 
for instance, economic conditions had some effect because 
patients’ had to purchase the CPAP device (it could not be 
provided by the study, nor is it covered by Mexico’s national 
health system). Also, several patients were unwilling to 
undergo CPAP titration because they had many medical 
appointments in different hospitals. Nonetheless, our study 
did have the second-largest series in terms of the number of 
patients studied using the reference standards and following 
the current guidelines for staging. Moreover, it is the first 
report to explore the CPAP titration process in patients with 
acromegaly. 
  In conclusion, there is a high frequency of sleep apnea in 
patients with acromegaly (97%), the majority of whom 
(90%) are candidates for CPAP treatment. In contrast to 
what is consistently observed in the general population, we 
did not identify any difference in the frequency of sleep 
apnea between men and women; nor did we observe patients 
with acromegaly under treatment with octreotide who had 
central sleep apnea. Our results thus provide evidence that, 
regardless of disease activity, acromegaly patients must be 
examined routinely to detect sleep apnea. Additional studies 
are required to explore whether CPAP treatment reduces the 
cardiovascular morbidity and mortality seen in patients with 
acromegaly. 
ACKNOWLEDGEMENTS 
  The authors wish to express their gratitude to the patients 
who kindly agreed to participate in this research, and to Dr. 
José Luis Carrillo Alduenda for his invaluable support 
during the realization of the study itself. The authors would 
also like to thank Mr. Paul Kersey (Language Laboratory, El 
Colegio de Michoacán) for correcting language use. 
CONFLICT OF INTEREST 
 Declared  none. 
REFERENCES 
[1]    Ben-Sholmo A, Melmed S. Acromegaly. Endocrinol Metab Clin 
North Am 2008; 37: 101-22. 
[2]  Mestron A, Webb SM, Astorga R, et al. Epidemiology, clinical 
characteristics, outcome, morbidity and mortality in acromegaly 
based on the Spanish Acromegaly Registry (Registro Espanol de 
Acromegalia, REA). Eur J Endocrinol 2004; 151: 439-46. 
[3]  Hochban W, Ehlenz K, Conradt R, Brandenburg U. Obstructive 
sleep apnoea in acromegaly: the role of craniofacial changes. Eur 
Respir J 1999; 14: 196-202. 
[4]  Isono S, Saeki N, Tanaka A, Nishino T. Collapsibility of passive 
pharynx in patients with acromegaly. Am J Respir Crit Care Med 
1999; 160: 64-8. 
[5]  Grunstein RR, Ho KY, Sullivan CE. Sleep apnea in acromegaly. 
Ann Intern Med 1991; 115: 527-32. Sleep Apnea and Acromegaly  The Open Respiratory Medicine Journal, 2012, Volume 6    33 
[6]  Rosenow F, Reuter S, Deuss U, et al. Sleep apnoea in treated 
acromegaly: relative frequency and predisposing factors. Clin 
Endocrinol (Oxf) 1996; 45: 563-9. 
[7]  Cook DM, Ezzat S, Katznelson L, et al. AACE Acromegaly 
Guidelines Task Force. AACE Medical Guidelines for Clinical 
Practice for the diagnosis and treatment of acromegaly. Endocr 
Pract 2004; 10: 213-25. 
[8]  Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly 
management: an update. J Clin Endocrinol Metab 2009; 94: 1509-
17. 
[9]  Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of 
acromegaly: a consensus statement. J Clin Endocrinol Metab 2000; 
85: 526-9. 
[10]  Chiner E, Arriero JM, Signes-Costa J, Marco J, Fuentes I. 
Validation of the Spanish version of the Epworth Sleepiness Scale 
in patients with a sleep apnea syndrome. Arch Bronconeumol 1999; 
35: 422-7. 
[11]  Iber C, Ancoli-Israel S, Chesson AL, Quan SF. The AASM Manual 
for the Scoring of Sleep and associated events. Rules, terminology 
and technical specifications. Westchester IL: American Academy 
of Sleep Medicine 2007. 
[12]  Loube DI, Gay PC, Strohl KP, Pack AI, White DP, Collop NA. 
Indications for positive airway pressure treatment of adult 
obstructive sleep apnea patients: a consensus statement. Chest 
1999; 115: 863-6. 
[13]  Fatti LM, Scacchi M, Pincelli AI, Lavezzi E, Cavagnini F. 
Prevalence and pathogenesis of sleep apnea and lung disease in 
acromegaly. Pituitary 2001; 4: 259-62. 
[14]  Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The 
occurrence of sleep-disordered breathing among middle-aged 
adults. N Engl J Med 1993; 328: 1230-5. 
[15]  Bouscoulet LT, Vazquez-Garcia JC, Muino A, et al. Prevalence of 
sleep related symptoms in four Latin American cities. J Clin Sleep 
Med 2008; 4: 579-85. 
[16]  Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the 
association between sleep-disordered breathing and hypertension. 
N Engl J Med 2000; 342: 1378-84. 
[17]  Gami AS, Howard DE, Olson EJ, Somers VK. Day-night pattern of 
sudden death in obstructive sleep apnea. N Engl J Med 2005; 352: 
1206-14. 
[18]  Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, 
Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and 
death. N Engl J Med 2005; 353: 2034-41. 
[19]  Torre-Bouscoulet L, Castorena-Maldonado A, Sada-Ovalle I, 
Meza-Vargas MS. Mechanisms of cardiovascular damage in 
obstructive sleep apnea. Rev Invest Clin 2008; 60: 502-16. 
[20]  Nussbaumer-Ochsner Y, Schuepfer N, Ulrich S, Bloch KE. 
Exacerbation of sleep apnoea by frequent central events in patients 
with the obstructive sleep apnea syndrome at altitude: a 
randomized trial. Thorax 2010; 65: 429-35. 
[21]  Hernández-Zenteno RJ, Pérez-Padilla R, Vázquez JC. Normal 
breathing during sleep at an altitude of 2,240 meters. Arch Med 
Res 2002; 33: 489-94 
[22]  Young T, Shahar E, Nieto FJ, et al. Predictors of sleep-disordered 
breathing in community-dwelling adults: the sleep heart health 
study. Arch Intern Med 2002; 162: 893-900. 
[23]  Grunstein RR, Ho KK, Sullivan CE. Effect of octreotide, a 
somatostatin analog, on sleep apnea in patients with acromegaly. 
Ann Intern Med 1994; 121: 478-83. 
 
 
Received: April 29, 2012  Revised: May 6, 2012  Accepted: May 21, 2012 
 
© Hernández-Gordillo et al.; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) 
which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. 
 
 